+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases



Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases



Circulation Research 91(12): 1082-1084




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010238610

Download citation: RISBibTeXText

PMID: 12480806

DOI: 10.1161/01.RES.0000047874.80576.5A


Related references

Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Annals of Medicine 33(9): 623-634, 2002

Differential release of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in patients following alcohol induced myocardial infarction. Circulation 104(17 Supplement): II 305, October 23, 2001

Endothelin-1-mediated signaling in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in astrocytes. Investigative Ophthalmology & Visual Science 48(8): 3737-3745, 2007

N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. American Journal of Cardiology 96(1): 31-34, 2005

Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion. Circulation 118(14 Suppl): S16-S23, 2008

Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovascular Therapeutics 30(1): 31-41, 2012

Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction. Journal of Surgical Research 172(1): 59-67, 2012

Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Failure Reviews 9(1): 53-61, 2004

Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiological Reviews 87(4): 1285-1342, 2007

Effect of simvastatin on serum matrix metalloproteinases-1, matrix metalloproteinases-9, tissue inhibitor of metalloproteinases-1, high sensitive C-reactive protein levels in patients of acute coronary syndrome in serum normocholesterolemia and hypercholesterolemia level. Zhonghua Xinxueguanbing Zazhi 32(2): 109-113, February 19, 2004

Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure. Zhonghua Yi Xue Za Zhi 86(24): 1693-1696, 2006

Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2). Matrix Biology 30(7-8): 404-412, 2012

Usefulness of examinations of serum levels of matrix metalloproteinases 1, MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1, hyaluronic acid and antibodies against cyclic citrullinated peptide in Lyme arthritis, rheumatoid arthritis and patients with arthritic complaints. Przeglad Epidemiologiczny 62 Suppl 1: 20-29, 2012

Usefulness of examinations of serum levels of matrix metalloproteinases 1, MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1, hialuronic acid and antibodies against cyclic citrullinated peptide in Lyme arthritis, rheumatoid arthritis and patients with arthritic complaints. Przeglad Epidemiologiczny: Supplement 1, 20-29, 2008